BRAF Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)

BRAF Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on BRAF Tests market for the year 2020 and beyond. Melanoma is accounted for as the nineteenth most basic malignant growth around the world, with assessed age-standardized frequency rates of 2.8-3.1 per 100,000. There is significant variety in frequency between nations, with the highest rates seen in Australia (37 for every 100,000) and the least in South-Central Asia (0.2 per 100,000). This pattern is ascribed to varieties in racial skin phenotype, just as contrasts in sun exposure around the globe. The fundamental environmental factor causing cutaneous melanoma is UV radiation.

Colorectal cancer (CRC) is the third most common cancer in men and the second most common cancer in women. Approximately 1.8 million new CRC incident cases were reported in 2018, according to the World Health Organization. Lung cancer is the second most common cancer with approximately 2.0 million new cases of lung cancer reported in 2018. Cigarette smoking is the dominant risk factor associated with lung cancer across all age groups, with approximately 80% of male and 45% of female lung cancer cases worldwide attributed to smoking.

The BRAF gene gives guidelines to making a protein that transmits specific signals from outside the cell to the cell’s nucleus. This protein is a piece of a signaling pathway known as the RAF/MAPK pathway, which controls a few significant cell functions. In particular, the RAF/MAPK pathway directs the development and division (proliferation) of cells, the procedure by which cells develop to specific functions (differentiation), cell movement (migration), and the implosion of cells (apoptosis). Chemical signaling through this pathway is basic for typical development before birth.

The BRAF tests include BRAF Immunohistochemistry (IHC), BRAF Sanger sequencing, BRAF Nucleic Acid Amplification Tests (NAATs) and BRAF other Tests (BRAF In Situ Hybridization (ISH), BRAF MassArray).

Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed BRAF Tests and evolving competitive landscape:

– Insightful review of the key industry trends.

– Annualized total BRAF Tests market revenue by segment and market outlooks from 2015-2030.

– Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

– Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.

– SWOT analysis for BRAF Tests market.

– Competitive dynamics insights and trends provided for BRAF Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

– Country specific overview of the healthcare system.

– Country specific reimbursement policies.

– Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: F. Hoffmann-La Roche Ltd, bioMérieux SA, Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Amoy Diagnostics Co Ltd, Abbott Laboratories, Biocartis SA, Others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.


Who should buy this report?

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:

CMO executives who must have deep understanding of the BRAF Tests market place to make strategic planning and investment decisions.

Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.

Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to buy

The model will enable you to:

Understand the impact of COVID-19 on BRAF Tests market.

Develop and design you’re in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving BRAF Tests market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BRAF Tests market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track device sales in the global and country-specific BRAF Tests market from 2015-2030.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

F. Hoffmann-La Roche Ltd, bioMérieux SA, Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Amoy Diagnostics Co Ltd, Abbott Laboratories, Biocartis SA, Others


Discounts available for multiple purchases.
+44 20 7947 2745

Join our mailing list

Saved reports